U.S. Markets open in 5 hrs.

Sanofi (SNY)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
49.15+0.08 (+0.16%)
At close: 4:02PM EDT
People also watch
NVSGSKAZNLLYNVO
Interactive chart
Previous Close49.07
Open49.01
Bid0.00 x
Ask0.00 x
Day's Range48.83 - 49.20
52 Week Range36.81 - 50.24
Volume5,230,204
Avg. Volume1,718,037
Market Cap117.16B
Beta0.75
PE Ratio (TTM)24.81
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.58 (3.21%)
Ex-Dividend Date2017-05-11
1y Target EstN/A
Trade prices are not sourced from all markets
  • Market Realist19 hours ago

    Gardasil and Merck’s Vaccines Business in 1Q17

    Gardasil is Merck's (MRK) leading vaccine franchise. Total sales for Gardasil in 1Q17 were $532.0 million, a ~41.0% rise over $378.0 million in 1Q16.

  • Regeneron, Sanofi Undercut Amgen, AbbVie In Rheumatoid Arthritis
    Investor's Business Dailyyesterday

    Regeneron, Sanofi Undercut Amgen, AbbVie In Rheumatoid Arthritis

    Regeneron and Sanofi's rheumatoid arthritis drug is 15%-30% cheaper than rival drugs from Amgen, AbbVie and Roche, an analyst said Tuesday.

  • American City Business Journals2 days ago

    ​Sanofi Genzyme takes on world’s top-selling drugs with new approval

    With Monday’s announcement that U.S. regulators have approved a drug for rheumatoid arthritis developed by Sanofi Genzyme and Regeneron Pharmaceuticals, the two drugmakers revealed a tried-and-true strategy to take on the world’s number one and number three best-selling drugs, which also happen to be for that same disease: give it a lower price. Cambridge-based Sanofi Genzyme (SNY) and Tarrytown, N.Y.-based Regeneron (REGN) will market their new drug, which has the generic name of sarilumab, under the name of Kevzara. Rheumatoid arthritis affects about 1.3 million Americans, mostly women, and Kevzara is approved for those with moderate to severe forms of the disease that aren’t well treated by other drugs.